ArticleProceedings of the National Academy of Sciences of the United States of America2013
Fas expression by tumor stroma is required for cancer eradication.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- CD8Science advances · 2025Article
- The role of CD8Heliyon · 2024Review
- IFNγ binding to extracellular matrix prevents fatal systemic toxicity.Nature immunology · 2023Article
- IFN-γ-dependent tumor-antigen cross-presentation by lymphatic endothelial cells promotes their killing by T cells and inhibits metastasis.Science advances · 2022Article
- CD8Nature reviews. Immunology · 2022Review
- The role of CD4 T cells in rejection of solid tumors.Current opinion in immunology · 2022Review
- Article
- DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Article
- Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo.ACS omega · 2020Article
- Article
- Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.Nature communications · 2017Article
- Article
- T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice.Oncotarget · 2017Article
- Evaluating frequency and quality of pathogen-specific T cells.Nature communications · 2016Article
- Preventing tumor escape by targeting a post-proteasomal trimming independent epitope.The Journal of experimental medicine · 2016Article
- Gene therapy as a potential tool for treating neuroblastoma-a focused review.Cancer gene therapy · 2016Review
- CD8 engineered cytotoxic T cells reprogram melanoma tumor environment.Oncoimmunology · 2016Article
- Targeting cancer-specific mutations by T cell receptor gene therapy.Current opinion in immunology · 2015Review
- Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.Cancer immunology research · 2015Article
- The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.Immunological reviews · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The contribution of molecules such as perforin, IFN-γ (IFNγ), and particularly Fas ligand (FasL) by transferred CD8(+) effector T (T(E)) cells to rejection of large, established tumors is incompletely understood. Efficient attack against large tumors carrying a surrogate tumor antigen (mimicking a "passenger" mutation) by T(E) cells requires action of IFNγ on tumor stroma cells to avoid selection of antigen-loss variants. Because "cancer-driving" antigens (CDAs) are rarely counterselected, IFNγ may be expected to be dispensable in elimination of cancers by targeting a CDA. Here, initial regression of large, established tumors required neither IFNγ, FasL, nor perforin by transferred CD8(+) T(E) cells targeting Simian Virus (SV) 40 large T as CDA. However, cytotoxic T(E) cells lacking IFNγ or FasL could not prevent relapse despite retention of the rejection antigen by the cancer cells. Complete tumor rejection required IFNγ-regulated Fas by the tumor stroma. Therefore, T(E) cells lacking IFNγ or FasL cannot prevent progression of antigenic cancer because the tumor stroma escapes destruction if its Fas expression is down-regulated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.